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Letters to the Editoror functional mitral valve disease is
decreased cardiac output, which is
compensated for by left ventricular
dilatation. Both mechanisms are
responsible for the symptoms. This
approach was confirmed by Coutinho
and colleagues1 (left atrial diameter,
52.3  8.7 vs 60.6  9.4 mm; P<
.0001; left ventricular end-diastolic
dimension, 65.8  9.6 vs 58.5  8.3
mm; P< .0001; left ventricular end-
systolic dimension, 46.1  9.3 vs
37.8  8.3 mm; P<.0001; and mean
pulmonary arterial systolic pressure,
53.1  16.7 vs 60.9  17.1 mm Hg;
P ¼ .004). In addition, the pre-
served left ventricular functions were
demonstrated in the mitral replace-
ment group (shortening fraction
30.2%  8.0% vs 35.5%  8.5%;
P<.000).1
When degenerative and functional
mitral valve disease subgroups were
compared between the mitral valve
repair and mitral replacement groups
in terms of cumulative patient sur-
vival, a statistically significant differ-
ence would have been detected. This
situation was shown by Coutinho and
colleagues1 in their Figure 1, C. In a
prospective study including patients
with degenerative etiology, a better
positive remodeling was observed by
Pandis and coworkers2 in their
repair group versus their replacement
group.2 A retrospective study
including 439 patients by Athanaso-
poulos and associates3 indicated that
when mitral regurgitation remained
untreated surgically until left ventric-
ular diameter were moderately to
severely abnormal or the left atrium
was moderately or severely dilated,
successful reverse remodeling became
less likely.
In conclusion, we speculate that
had major valve-related adverse
events been neglected, better survival
would have been observed in the
mitral replacement group because of
better preserved left ventricular func-
tions and dimensions. Likewise, if
inadequate left ventricular reverse re-
modeling were neglected, better1994 The Journal of Thoracic andsurvival would have been observed
in the mitral valve repair group.
Finally, adding major valve-related
adverse events and inadequate left
ventricular reverse remodeling to the
calculation equalized the overall sur-
vival between the two groups.
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We thank Tavlasoglu and co-
workers for the contribution of their
letter to the interesting discussion
about the decision to replace or repair
the mitral valve in double valve sur-
gery (aortic and mitral). Despite the
existence of a significant number of
reports in the literature dealing with
concomitant aortic and mitral valve
surgery, few have directly addressed
this question. Some would argue that
if the aortic valve needs replacement
with a prosthesis, an additional mitral
prosthesis should not alter the
outcome significantly.
One landmark study that ap-
proached this subject in a methodical
way for the first time was published
by the Cleveland Clinic group1; how-
ever, there were differences between
their study population and our own,2
namely the prevalence of rheumatic
disease, which would cause one to
expect different results. In the Cleve-
land Clinic study, 70% of the mitral
valves had rheumatic involvement,
whereas nearly two-thirds of our pa-
tients had secondary (functional) or
degenerative mitral disease. Our pop-
ulation is more consistent with the
current daily practice in Western
countries, because rheumatic etiology
is declining. Furthermore, secondary
(nonischemic and non–dilated cardio-
myopathy) mitral regurgitation in the
context of aortic valve disease is gain-
ing importance,3 because patients are
increasingly older, and moderate or
moderate-to-severe mitral regurgita-
tion is frequently found. It is thus
important to know the outcome (sur-
vival and event-free survival) after
repair or replacement of the mitral
valve.
One major limitation of our study
was the heterogeneity of the popula-
tion; the groups (repair vs replace-
ment) were very different with
regard to important variables.
Letters to the EditorNaturally, the decision to repair or to
replace was influenced by the charac-
teristics of the patient and of the valve,
and a repair was preferred whenever
possible, which may have created a
bias. This was the rationale for per-
forming propensity score matching
to obtain more similar groups for com-
parison, a well-known and accepted
statistical method for this type of anal-
ysis. Relevant demographic, patient,
and echocardiographic characteris-
tics, including mitral valve pathology,
were included in the propensity score
analysis.
We could not demonstrate a clear
survival benefit in the repair group,
but we can also hypothesize as to rea-
sons for this fact. First all, we recog-
nize that we unfortunately do not yet
have a long follow-up time (up to
12.5 years, mean 5.4 years), and we
believe that a longer study might
have shown evidence of that advan-
tage. Second, the small number of pa-
tients subjected to comparison may
have also influenced the analysis. We
have to acknowledge, however, the
possibility that there is simply no sur-
vival benefit associated with repairing
the mitral valve. Nevertheless, mitral
valve repair showed advantage in pa-
tients older than 65 years (P ¼ .017)
and for nonrheumatic etiology (P ¼
.034). A very recent article from
Gaur and colleagues,4 due to be pub-
lished in this Journal, supports our
finding, stating that ‘‘elderly patients
with mitral regurgitation who undergo
MVP [repair] have better postopera-
tive outcomes, lower operative mor-
tality, and improved long-term
survival than those undergoing MVR
[replacement].’’ Regarding the latter,
we intuitively believe that it is better
to repair than to replace a degenerative
mitral valve, because there is enough
evidence accumulated in the literature
favoring that approach.5
Our study implies some important
take-home messages. First, double
valve surgery can be performed
with low mortality (nearly 1%),
whether repairing or replacing theThe Journalmitral valve. Second, major adverse
valve events are more common with
mitral replacement. Third, there was
only a survival advantage in repair
for older patients with nonrheumatic
valves. Overall, we believe that
mitral valve repair is the best option
in the setting of concomitant aortic
valve replacement.
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PERCUTANEOUS
VENOARTERIAL
EXTRACORPOREAL
MEMBRANE OXYGENATION
ACCESS TO A PERIPHERAL
ARTERIAL CANNULATION: IS
IT SAFE?
To the Editor:
We read with interest the elegant
article by Demertzis and Carrel1
dealing with the technical approach of
peripheral cannulation ofof Thoracic and Cardiovascular Surgerextracorporeal membrane oxygenation
(ECMO). Indeed, the considerable re-
newed interest in and accumulating ev-
idence for the use of ECMO during the
last few years is likely attributable to
the observed improvements in extra-
corporeal technology.
Since 2005, when Leprince and co-
workers2 published the first series of
ECMO cases, the most significant
benefit of ECMO has been observed
in the setting of cardiogenic shock
related to myocardial infarction or to
end-stage chronic heart failure. In
this setting and for this type of patient,
diminishing the time between the
initiation of shock and the start of cir-
culatory assistance becomes the main
concern of the surgical staff. In this
context, the cannulation of the
ECMO device through a percutaneous
technique has become a trendy
approach to gain time. Unfortunately,
we have forgotten that these patients
may have peripheral arterial diseases
and a consequent high incidence of
calcified arteries, a situation that
makes the use of the percutaneous
technique much less indicated.
Demertzis and Carrel1 have
described a very attractive surgical
technique to convert a percutaneous
technique into an open access one. In
this regard, we have some comments.
The most important drawback of
the use of femoral artery prostheses
is the risk of infection, in particular
for patients waiting for a heart trans-
plant or for LVAD implantation. On
the other hand, during the last few
years the most useful technique has
been the Seldinger technique
following a surgical incision with a re-
perfusion cannula placed in the super-
ficial femoral artery. The current
procedure is a way of avoiding any
hazardous puncture, particularly in
the case of patients with low flow
and low pulsatility or cardiac arrest.
Moreover, this practice also allows
the visualization of the vascular inser-
tion of the cannula, a situation that isy c Volume 147, Number 6 1995
